Citations

Mayo Clinic

Showing 10 of 108602 citations.

Perturbation-Based Training on Compliant Surfaces to Improve Balance in Children With Cerebral Palsy: A Feasibility Study
Phillips, Connor , Phan, Vu , Jo, Kwanghee, Save, Omik , Russell, Joshua, Zeien, Kayla B., Eikenberry, Megan , Kinney, Carolyn L. , Lee, Hyunglae , Kinney, Carolyn , Russell, Joshua B.

IEEE Transactions on Medical Robotics and Bionics | April 12, 2023 | Volume: 5 | Issue: 2 | Pages: 242-252

10.1109/tmrb.2023.3265711 Get It

Translational relevance of SOS1 targeting for KRAS‐mutant colorectal cancer
Alem, Diego , Beato, Francisca , Sarcar, Bhaswati , Tassielli, Alexandra F. , Dai, Ruifan , Hogenson, Tara L. , Park, Margaret A. , Yuan, Yu, Fernández-Zapico, Martín E. , Tan, Aik Choon , Fleming, Jason B. , Tan, Aik Choon , Yang, Xinrui , Jiang, Kun , Cai, Jianfeng , Xie, Hao

Molecular Carcinogenesis | April 12, 2023 | Volume: 62 | Issue: 7 | Pages: 1025-1037

10.1002/mc.23543 | PMID 37042566 Get It

AbstractIt has been challenging to target mutant KRAS (mKRAS) in colorectal cancer (CRC) and other malignancies. Recent efforts have focused on developing inhibitors blocking molecules essential for KRAS activity. In this regard, SOS1 inhibition has arisen as an attractive approach for mKRAS CRC given its essential role as a guanine nucleotide exchange factor for this GTPase. Here, we demonstrated the translational value of SOS1 blockade in mKRAS CRC. We used CRC patient‐derived organoids (PDOs) as preclinical models to evaluate their sensitivity to SOS1 inhibitor BI3406. A combination of in silico analyses and wet lab techniques was utilized to define potential predictive markers for SOS1 sensitivity and potential mechanisms of resistance in CRC. RNA‐seq analysis of CRC PDOs revealed two groups of CRC PDOs with differential sensitivities to SOS1 inhibitor BI3406. The resistant group was enriched in gene sets involving cholesterol homeostasis, epithelial−mesenchymal transition, and TNF‐α/NFκB signaling. Expression analysis identified a significant correlation between SOS1 and SOS2 mRNA levels (Spearman's ρ 0.56, p < 0.001). SOS1/2 protein expression was universally present with heterogeneous patterns in CRC cells but only minimal to none in surrounding nonmalignant cells. Only SOS1 protein expression was associated with worse survival in patients with RAS/RAF mutant CRC (p = 0.04). We also found that SOS1/SOS2 protein expression ratio >1 by immunohistochemistry (p = 0.03) instead of KRAS mutation (p = 1) was a better predictive marker to BI3406 sensitivity of CRC PDOs, concordant with the significant positive correlation between SOS1/SOS2 protein expression ratio and SOS1 dependency. Finally, we showed that GTP‐bound RAS level underwent rebound even in BI3406‐sensitive PDOs with no change of KRAS downstream effector genes, thus suggesting upregulation of guanine nucleotide exchange factor as potential cellular adaptation mechanisms to SOS1 inhibition. Taken together, our results show that high SOS1/SOS2 protein expression ratio predicts sensitivity to SOS1 inhibition and support further clinical development of SOS1‐targeting agents in CRC.
Interrater Reliability of Functional Lumen Imaging Probe Panometry and High-Resolution Manometry for the Assessment of Esophageal Motility Disorders
Chen, Joan W. , Khan, Abraham, Chokshi, Reena V. , Clarke, John O. , Garza, Jose M. , Gupta, Milli , Gyawali, C. Prakash , Jain, Anand , Katz, Philip O. , Konda, Vani J. , Lazarescu, Adriana , Lynch, Kristle L. , Schnoll‐Sussman, Felice , Vela, Marcelo F. , Schauer, Jacob M. , Pandolfino, John E. , Carlson, Dustin A. , Clarke, J , Gyawali, C P , Chen, Joan , Khan, Abraham, Fass, Ronnie , Spechler, Stuart Jon , Yadlapati, Rena , Kahrilas, Peter J.

American Journal of Gastroenterology | April 12, 2023 | Volume: 118 | Issue: 8 | Pages: 1334-1343

10.14309/ajg.0000000000002285 | PMID 37042784 Get It

INTRODUCTION: High-resolution manometry (HRM) and functional lumen imaging probe (FLIP) are primary and/or complementary diagnostic tools for the evaluation of esophageal motility. We aimed to assess the interrater agreement and accuracy of HRM and FLIP interpretations. METHODS: Esophageal motility specialists from multiple institutions completed the interpretation of 40 consecutive HRM and 40 FLIP studies. Interrater agreement was assessed using intraclass correlation coefficient (ICC) for continuous variables and Fleiss' κ statistics for nominal variables. Accuracies of rater interpretation were assessed using the consensus of 3 experienced raters as the reference standard. RESULTS: Fifteen raters completed the HRM and FLIP studies. An excellent interrater agreement was seen in supine median integral relaxation pressure (ICC 0.96, 95% confidence interval 0.95–0.98), and a good agreement was seen with the assessment of esophagogastric junction (EGJ) outflow, peristalsis, and assignment of a Chicago Classification version 4.0 diagnosis using HRM (κ = 0.71, 0.75, and 0.70, respectively). An excellent interrater agreement for EGJ distensibility index and maximum diameter (0.91 [0.90–0.94], 0.92 [0.89–0.95]) was seen, and a moderate-to-good agreement was seen in the assignment of EGJ opening classification, contractile response pattern, and motility classification (κ = 0.68, 0.56, and 0.59, respectively) on FLIP. Rater accuracy for Chicago Classification version 4.0 diagnosis on HRM was 82% (95% confidence interval 78%–84%) and for motility diagnosis on FLIP Panometry was 78% (95% confidence interval 72%–81%). DISCUSSION: Our study demonstrates high levels of interrater agreement and accuracy in the interpretation of HRM and FLIP metrics and moderate-to-high levels for motility classification in FLIP, supporting the use of these approaches for primary or complementary evaluation of esophageal motility disorders.
Affecting Computing in Multimodal Mobility
Dangi, Priyal, Garg, Muskan

Advances in Wireless Technologies and Telecommunication | April 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: 351-370

10.4018/978-1-6684-8582-8.ch019 Get It

Computational models that simulate human emotions have witnessed a substantial development in recent years for widening the spectrum of applications. Emotional computation is becoming crucial in human-to-computer interactions with exponential growth of artificial intelligence. Normally referred to as emotion recognition, it is widely believed that the prospective detection of a person's emotional state of mind should be computed from their facial expressions. Face-movement combinations may express many different emotion types, for instance, hate, anger, panic, joy, grief, surprise, shock, to name a few. The goal and emphasis of this manuscript is the deployment of different algorithms and computation models for emotions. Considerable advancements in this domain of emotion recognition can be made through AI model development that discusses the challenges of the system and Facial Action Coding as an integral part of the models.
Digital Health: A New Frontier
Barracca, Antonio, Ledda, Stefano, Mancosu, Gianmaria, Quintaliani, Giuseppe, Kashani, Kianoush , Kashani, Kianoush B , Ledda, Stefano, Mancosu, Gianmaria, Pintore, Giovanni , Ronco, Claudio

Journal of Translational Critical Care Medicine | April 12, 2023 | Volume: 5 | Issue: 2 | Pages: No page available

10.4103/jtccm-d-22-00018 Get It

ABSTRACT The Food and Drug Administration defines digital health (DH) as “a convergence of people, information, technology, and connectivity to improve health care and health outcomes”. Information and communication technologies are categorized under the DH umbrella. While still in their infancy, these technologies have great potential to revolutionize the clinical approaches to bedside management and overall health care. Over the past few decades, there has been a substantial improvement in the technology in smart wearable devices that enabled them to enhance their abilities to collect patient-related data, including physiological and behavioral information in the Internet of things. This has resulted in implementing several controlled clinical trials that have confirmed their validity and safety. These digital diagnostics have led to the expansion of digital therapies and specialized software (for example, apps) capable of effectively and measurably guiding patients’ progress toward improving their clinical condition. These technologies are clinically validated treatments for many diseases with particular effectiveness in pathological conditions related to behavior and psychological factors. In this review paper, we describe the outlines of some of the recent progress made in this field.
Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors
Morcos, Peter N. , Schlender, Jan, Burghaus, Rolf , Moss, Jonathan, Lloyd, Adam , Childs, Barrett H. , Macy, Margaret E. , Chung, John, Garmann, Dirk , Schlender, Jan‐Frederik , Moss, Jonathan, Reid, Joel M.

Clinical and Translational Science | April 12, 2023 | Volume: 16 | Issue: 7 | Pages: 1197-1209

10.1111/cts.13523 | PMID 37042099 Get It

AbstractCopanlisib is an intravenously administered phosphatidylinositol 3‐kinase (PI3K) inhibitor which was investigated in pediatric patients with relapsed/refractory solid tumors. A model‐informed approach was undertaken to support and confirm an empirically selected starting dose of 28 mg/m2 for pediatric patients ≥1 year old, corresponding to 80% of the adult recommended dose adjusted for body surface area. An adult physiologically based pharmacokinetic (PBPK) model was initially established using copanlisib physicochemical and disposition properties and clinical pharmacokinetics (PK) data and was shown to adequately capture clinical PK across a range of copanlisib doses in adult cancer patients. The adult PBPK model was then extended to the pediatric population through incorporation of age‐dependent anatomical and physiological changes and used to simulate copanlisib exposures in pediatric cancer patient age groups. The pediatric PBPK model predicted that the copanlisib 28 mg/m2 dose would achieve similar copanlisib exposures across pediatric ages when compared with historical adult exposures following the approved copanlisib 60 mg dose administered on Days 1, 8, and 15 of a 28‐day cycle. Clinical PK were collected from a phase I study in pediatric patients with relapsed/refractory solid tumors (aged ≥4 years). An established adult population PK model was extended to incorporate an allometrically‐scaled effect of body surface area and confirmed that the copanlisib maximum tolerated dose of 28 mg/m2 was appropriate to achieve uniform copanlisib exposures across the investigated pediatric age range and consistent exposures to historical data in adult cancer patients. The model‐informed approach successfully supported and confirmed the copanlisib pediatric dose recommendation.
Cellular senescence in skin‐related research: Targeted signaling pathways and naturally occurring therapeutic agents
Polańska, Adriana , Stawny, Maciej , Rubiś, Błażej, Nourredine, Sarah, Ashiqueali, Sarah , Schneider, Augusto , Wyles, Saranya P. , Kirkland, James L. , Tchkonia, Tamara, Masternak, Michal M , Ashiqueali, Sarah A , Dańczak‐Pazdrowska, Aleksandra , Gornowicz‐Porowska, Justyna , Krajka‐Kuźniak, Violetta , Gostyńska, Aleksandra , Rubiś, Błażej, Tchkonia, Tamar

Aging Cell | April 12, 2023 | Volume: 22 | Issue: 6 | Pages: No page available

10.1111/acel.13845 | PMID 37042069 Get It

AbstractDespite the growing interest by researchers into cellular senescence, a hallmark of cellular aging, its role in human skin remains equivocal. The skin is the largest and most accessible human organ, reacting to the external and internal environment. Hence, it is an organ of choice to investigate cellular senescence and to target root‐cause aging processes using senolytic and senomorphic agents, including naturally occurring plant‐based derivatives. This review presents different aspects of skin cellular senescence, from physiology to pathology and signaling pathways. Cellular senescence can have both beneficial and detrimental effects on the skin, indicating that both prosenescent and antisenescent therapies may be desirable, based on the context. Knowledge of molecular mechanisms involved in skin cellular senescence may provide meaningful insights for developing effective therapeutics for senescence‐related skin disorders, such as wound healing and cosmetic skin aging changes.
Pie‐Net: Prior‐information‐enabled deep learning noise reduction for coronary CT angiography acquired with a photon counting detector CT
Chang, Shaojie , Huber, Nathan R. , Marsh, Jeffrey F., Koons, Emily K. , Gong, Hao , Yu, Lifeng , Yu, Lifeng , McCollough, Cynthia H. , Leng, Shuai

Medical Physics | April 12, 2023 | Volume: 50 | Issue: 10 | Pages: 6283-6295

10.1002/mp.16411 | PMID 37042049 Get It

AbstractBackgroundPhoton‐counting‐detector CT (PCD‐CT) enables the production of virtual monoenergetic images (VMIs) at a high spatial resolution (HR) via simultaneous acquisition of multi‐energy data. However, noise levels in these HR VMIs are markedly increased.PurposeTo develop a deep learning technique that utilizes a lower noise VMI as prior information to reduce image noise in HR, PCD‐CT coronary CT angiography (CTA).MethodsCoronary CTA exams of 10 patients were acquired using PCD‐CT (NAEOTOM Alpha, Siemens Healthineers). A prior‐information‐enabled neural network (Pie‐Net) was developed, treating one lower‐noise VMI (e.g., 70 keV) as a prior input and one noisy VMI (e.g., 50 keV or 100 keV) as another. For data preprocessing, noisy VMIs were reconstructed by filtered back‐projection (FBP) and iterative reconstruction (IR), which were then subtracted to generate “noise‐only” images. Spatial decoupling was applied to the noise‐only images to mitigate overfitting and improve randomization. Thicker slice averaging was used for the IR and prior images. The final training inputs for the convolutional neural network (CNN) inside the Pie‐Net consisted of thicker‐slice signal images with the reinsertion of spatially decoupled noise‐only images and the thicker‐slice prior images. The CNN training labels consisted of the corresponding thicker‐slice label images without noise insertion. Pie‐Net's performance was evaluated in terms of image noise, spatial detail preservation, and quantitative accuracy, and compared to a U‐net‐based method that did not include prior information.ResultsPie‐Net provided strong noise reduction, by 95 ± 1% relative to FBP and by 60 ± 8% relative to IR. For HR VMIs at different keV (e.g., 50 keV or 100 keV), Pie‐Net maintained spatial and spectral fidelity. The inclusion of prior information from the PCD‐CT data in the spectral domain was able to improve a robust deep learning‐based denoising performance compared to the U‐net‐based method, which caused some loss of spatial detail and introduced some artifacts.ConclusionThe proposed Pie‐Net achieved substantial noise reduction while preserving HR VMI's spatial and spectral properties.
The First Survival Score for Patients Treated with Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost for Brain Metastases
Rades, Dirk , JOHANNWERNER, LEONIE, Werner, Elisa, Cremers, Florian , Yu, Nathan Y. , Yu, Nathan

Biology | April 12, 2023 | Volume: 12 | Issue: 4 | Pages: 585

10.3390/biology12040585 | PMID 37106785 Get It

A modern approach for brain metastases includes whole-brain radiotherapy plus simultaneous boost (WBRT+SIB). We developed a survival score in 128 patients treated with WBRT+SIB. Three models, each including three prognostic groups, were created. Positive predictive values (PPVs) for death ≤6 and survival ≥6 months were calculated. On multivariate analyses, performance score (KPS) and the number of brain metastases were significantly associated with survival. On univariate analyses, age showed a strong trend, and extra-cerebral cranial metastases a trend. In Model 1 (KPS, number of lesions), compared groups had 6-month survival rates of 15%, 38% and 57%. In Model 2 (KPS, lesions, age), rates were 17%, 33% and 75%, and in Model 3 (KPS, lesions, age, extra-cerebral metastases), 14%, 34% and 78%. PPVs for death ≤6 and survival ≥6 months were 85% and 57% (Model 1), 83% and 75% (Model 2), and 86% and 78% (Model 3). Thus, all models were accurate in predicting death ≤ 6 months; poor-prognosis patients may not benefit from SIB. Models 2 and 3 were superior in predicting survival ≥ 6 months. Given that Model 3 requires more data (including extensive staging), Model 2 is considered favorable for many patients. If extra-cerebral metastases are already known or extensive staging has been performed, Model 3 can also be used.
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms
Dueck, Amylou C. , Palmer, Jeanne , Sproat, Lisa, Hashmi, Shahrukh K. , Mesa, Ruben A. , Litzow, Mark R. , Al‐Kali, Aref , Dueck, A. C. , Palmer, Jeanne M , Hashmi, Shahrukh K , Mesa, Ruben , Al-Kali, Aref , Tibes, Raoul , Kosiorek, Heidi , Bogenberger, James M. , Hogan, William J.

Cancer | April 12, 2023 | Volume: 129 | Issue: 15 | Pages: 2321-2330

10.1002/cncr.34800 | PMID 37042080 Get It

AbstractBackgroundMyeloid neoplasms (myelodysplastic syndrome [MDS], myelofibrosis, and chronic myelomonocytic [CMML]) are aggressive hematological malignancies for which, despite recent approvals, novel therapies are needed to improve clinical outcomes. The hedgehog (HH) pathway is one of the main pathways for cancer stem cells survival and several HH inhibitors (HHi) are approved in clinical practice.MethodsSonidegib (SON), an oral HHi, was tested in this phase 1/1b trial in combination with azacitidine (AZA, 75 mg/m2 days ×7) in patients with newly diagnosed and relapsed/refractory (r/r) chronic MN or acute myeloid leukemia (AML).ResultsSixty‐two patients (28 [45%] newly diagnosed) were treated in this study, including 10 patients in the dose‐finding component and 52 patients in phase 1b. SON 200 mg oral daily on days 1–28 each cycle was deemed the recommended dose for phase 1b. Out of 21 rrAML patients, two achieved response (one complete response/one morphologic leukemia‐free state) with no responses seen in seven r/r MDS/CMML patients. In newly diagnosed AML/MDS, response was seen in six (three had complete remission, two had morphological leukemia‐free status) of 27 patients. Median overall survival was 26.4 and 4.7 months for newly diagnosed MDS and AML, respectively. Safety was satisfactory with common (>20%) side effects including fatigue, constipation, nausea, cough, insomnia, and diarrhea. Only 7% of patients died in the study, and none of the deaths were deemed related to treatment.ConclusionsOur study shows that AZA + SON are a safe combination in a patient with MN. Similar to other hedgehog inhibitors, this combination yielded limited response rate in patients with myeloid neoplasms.